Opinion|Videos|January 29, 2025
Educating Patients on Systemic Prurigo Nodularis Treatment and Adherence
Author(s)TJ Chao, MPAS, PA-C
TJ Chao, MPAS, PA-C, discusses how to approach conversations with patients about starting systemic therapy for prurigo nodularis, emphasizing the importance of setting realistic treatment expectations, promoting long-term adherence, and providing tips for managing biologic agents administered on a bimonthly or monthly basis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you approach the conversation with patients when starting a systemic agent?
- How do you set treatment expectations to ensure adherence to systemic therapy, and what kind of tips can you share about long-term goals of treatment?
- Provide ways to promote adherence with these biologic agents as they are given on a bi-monthly or monthly basis.
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Disc Medicine reports the phase 3 APOLLO trial met all primary and secondary end points, with whole-blood PPIX reduced 41.4% vs placebo and an NDA resubmission planned by end of 2026.
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
Advertisement
Advertisement
Trending on Dermatology Times
1
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
2
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
5